Senti Biosciences Inc (SNTI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.38M
Last updated: Nov 17, 2026 at 11:06 AM ET
Senti Biosciences Inc (SNTI) Financials: Revenue, Profit and Cash Flow
Senti Biosciences reported revenue of $22.00K for the fiscal year ended Dec 31, 2025. That year, net income was -$61.44M with a net margin of -279263.6%, operating cash flow was -$43.44M and free cash flow was -$43.64M. The quarter ended Sep 30, 2026 had revenue of $19.00K and net income of -$11.59M.
Revenue and Margins
Over the 6 years to Dec 2025, revenue fell from $85.00K, a compound annual decline of 20.2%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $22.00K | N/A | 100.0% | -312631.8% | -279263.6% |
| Dec 2024 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2023 | $2.56M | -40.2% | 100.0% | -3620.7% | -2774.6% |
| Dec 2022 | $4.29M | +55.2% | 100.0% | -1448.5% | -1358.1% |
| Dec 2021 | $2.76M | +600.8% | 100.0% | -1464.9% | -2003.6% |
| Dec 2020 | $394.00K | +363.5% | 100.0% | -6267.5% | -5041.1% |
| Dec 2019 | $85.00K | N/A | -16987.1% | -25625.9% | -24890.6% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $22.00K | $0 | $2.56M | $4.29M | $2.76M | $394.00K | $85.00K |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $15.96M | $14.52M |
| Gross profit | $22.00K | $0 | $2.56M | $4.29M | $2.76M | $394.00K | -$14.44M |
| Research and development | $37.59M | $34.36M | $32.15M | $28.14M | $21.96M | $15.96M | $14.52M |
| Operating income | -$68.78M | -$61.04M | -$92.73M | -$62.08M | -$40.45M | -$24.69M | -$21.78M |
| Net income | -$61.44M | -$52.79M | -$71.06M | -$58.21M | -$55.32M | -$19.86M | -$21.16M |
| EBITDA | -$58.92M | -$49.85M | -$81.91M | -$49.09M | N/A | -$22.71M | -$21.36M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.00K | $17.00K | $16.00K | $22.00K | $0 | $0 | $0 | $5.86M | $0 | $0 | $0 | $333.00K |
| Gross profit | $19.00K | $17.00K | $16.00K | $22.00K | $0 | $0 | $0 | -$1.46M | $0 | $0 | $0 | -$1.14M |
| Operating income | -$12.32M | -$14.49M | -$4.62M | -$18.64M | -$16.95M | -$16.80M | -$16.40M | -$16.17M | -$15.21M | -$13.36M | -$16.30M | -$18.70M |
| Net income | -$11.59M | -$12.75M | -$4.22M | -$14.47M | -$18.13M | -$14.73M | -$14.11M | -$610.00K | -$28.87M | -$11.20M | -$12.11M | -$18.72M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $16.42M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Total assets | $51.22M | $97.84M | $119.48M | $180.79M | $96.70M | $48.34M | $35.84M |
| Current assets | $23.27M | $58.96M | $71.20M | $102.58M | $60.19M | $31.71M | $18.76M |
| Cash and equivalents | $16.42M | $48.28M | $35.93M | $57.62M | $56.03M | $30.54M | $5.30M |
| Total liabilities | $45.63M | $47.09M | $52.57M | $53.53M | $36.33M | $107.06M | $17.88M |
| Short-term debt | $0 | $4.75M | $4.13M | $1.99M | $1.74M | $1.52M | N/A |
| Shareholder equity | $5.59M | $25.65M | $66.91M | $127.26M | -$111.46M | -$58.71M | $17.96M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $28.36M | $33.10M | $38.24M | $51.22M | $52.69M | $68.54M | $82.78M | $97.84M | $57.72M | $86.91M | $102.19M | $119.48M |
| Total liabilities | $37.96M | $36.51M | $35.68M | $45.63M | $44.56M | $43.89M | $44.92M | $72.19M | $41.73M | $42.77M | $46.09M | $52.57M |
| Cash and equivalents | $5.55M | $6.46M | $8.94M | $16.42M | $12.24M | $21.58M | $33.80M | $48.28M | $10.48M | $15.86M | $23.72M | $35.93M |
| Shareholder equity | -$9.60M | -$3.40M | $2.56M | $5.59M | $8.12M | $24.65M | $37.86M | $25.65M | $15.99M | $44.15M | $56.09M | $66.91M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$43.44M | -$41.40M | -$52.40M | -$34.90M | -$34.63M | -$24.17M | -$18.38M |
| Capital expenditures | $196.00K | $26.00K | $12.04M | $41.37M | $5.54M | $1.16M | $2.00M |
| Free cash flow | -$43.64M | -$41.42M | -$64.43M | -$76.27M | -$40.18M | -$25.33M | -$20.37M |
| Dividends paid | N/A | N/A | $404.00K | $5.17M | $3.89K | N/A | N/A |
| Share repurchases | $2.47M | $229.00K | $0 | N/A | N/A | N/A | N/A |
| Investing cash flow | -$184.00K | $34.00K | $30.08M | -$81.96M | -$5.54M | $11.36M | $3.75M |
| Financing cash flow | $11.76M | $53.73M | $779.00K | $118.55M | $68.44M | $38.05M | $14.01M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.73M | -$14.25M | -$7.48M | -$6.88M | -$9.45M | -$13.07M | -$14.05M | -$13.50M | -$7.87M | -$8.35M | -$11.68M | -$7.04M |
| Capital expenditures | N/A | N/A | $0 | $0 | $0 | $196.00K | $0 | $11.00K | $0 | $0 | $15.00K | $4.00K |
| Free cash flow | N/A | N/A | -$7.48M | -$6.88M | -$9.45M | -$13.27M | -$14.05M | -$13.52M | -$7.87M | -$8.35M | -$11.70M | -$7.04M |
Frequently Asked Questions About SNTI
What is Senti Biosciences' annual revenue?
Senti Biosciences reported revenue of $22.00K for the fiscal year ended Dec 31, 2025.
Is Senti Biosciences profitable?
No. Senti Biosciences reported net income of -$61.44M for the fiscal year ended Dec 31, 2025, with a net margin of -279263.6%.
How much free cash flow does SNTI generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$43.44M minus capital expenditures of $196.00K produced free cash flow of -$43.64M.
How much debt does Senti Biosciences have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $16.42M.
What is SNTI's profit margin?
For the fiscal year ended Dec 31, 2025, Senti Biosciences reported gross margin of 100.0%, operating margin of -312631.8% and net margin of -279263.6%.
SNTI pages: Overview, Earnings, Forecast, Financials, Competitors